The phase 2/3 trials of Covaxin for inoculation in children under the age of 18 have concluded, according to Bharat Biotech, a Hyderabad-based biotechnology firm and the manufacturers of the Covaxin Covid-19 vaccine. The business also stated that the data would be sent to the Drug Controller General of india (DCGI) by the end of next week.

Krishna Ella, chairman and managing director of Bharat Biotech, also stated that data analysis for the trials is presently in progress and that the report would be submitted soon. The number of volunteers (subjects) is approaching 1,000.

Furthermore, the company's intranasal vaccination against Covid-19 is scheduled to complete phase 2 trials by the end of September. The intranasal vaccination induces an immune response in the nose, which serves as a site of entry for the virus into the human body, protecting against infection and virus transmission.


The intranasal vaccination studies are being done on around 650 participants who have been divided into three cohorts. According to Ella, the first group got Covaxin as the first dosage and intranasal shots as the second, the second group got intranasal shots for both doses, and the third group got it for the first dose and Covaxin for the second. He went on to say that each dose was given after a 28-day break.

Ella claimed that the manufacturing of Covaxin will reach 55 million doses in October, up from 35 million doses in September.

మరింత సమాచారం తెలుసుకోండి:

Vaccine for Childrens

Sachin

21/09/2021 05:00 PM